JPRN-jRCT1041200068
Active, not recruiting
Phase 2
Phase II study of atezolizumab and bevacizumab combination therapy for the patients with advanced hepatocellular carcinoma previously treated with systemic chemotherapy
Yamashita Tatsuya0 sites28 target enrollmentNovember 25, 2020
Conditionshepatocellular carcinoma
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- hepatocellular carcinoma
- Sponsor
- Yamashita Tatsuya
- Enrollment
- 28
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; previously treated by systemic therapy; Preserved liver function; 20 years or older; ECOG Performance status \<\=2; preservation of major organ function; written informed consent
Exclusion Criteria
- •refractory ascites or pleural effusion; risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
Phase II study of atezolizumab plus bevacizumab combination therapy for the patients with unresectable hepatocellular carcinoma and Child-Pugh BHepatocellular carcinomaSystemic therapyJPRN-jRCTs031210355Ikeda Masafumi30
Completed
Phase 2
A Phase II Study of Atezolizumab with Bevacizumab for Patients with Non-Small Cell Non-Squamous Cell Lung Cancer (At Be Study) (Investigator-Initiated Clinical Trial)non-small-cell lung cancerJPRN-jRCT2080223980Takashi Seto (Coordinating Investigator)38
Recruiting
Phase 2
Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/BevacizumabHepatocellular Carcinoma Non-resectableNCT04224636Ludwig-Maximilians - University of Munich106
Active, not recruiting
Phase 1
Evaluation of treatment combination Atezolizumab/Bevacizumab +/- Chemotherapy in patients with recurrent ovarian cancerEfficacy of atezolizumab in combination with non-platinum based chemotherapy and bevacizumab versus the combination of a non-platinum based chemotherapy and bevacizumab in recurrent ovarian cancerMedDRA version: 27.0Level: PTClassification code 10016182Term: Fallopian tube cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 27.0Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-000202-37-LTAGO Research GmbH550
Active, not recruiting
Phase 1
Evaluation of treatment combination Atezolizumab/Bevacizumab +/- Chemotherapy in patients with recurrent ovarian cancerEUCTR2017-000202-37-NOAGO Research GmbH664